FIELD: medicine.
SUBSTANCE: what is presented is the preventive use of an opioid receptor blocker 'CTAP' as an agent improving the cardiac resistance to ischemic and following reperfusion injuries. What is shown is an ability of 'CTAP' to prevent the above injuries (to reduce a necrosis area and a risk area) when introduced 25 min before the 30-minute coronary occlusion and the following 3-hour reperfusion.
EFFECT: invention may be used for creating the new effective agent improving the cardiac resistance to ischemic and following reperfusion injuries.
2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SIMULATION OF INCREASED STABILITY OF RAT MYOCARDIUM TO ISCHEMIC-REPERFUSION DAMAGE | 2016 |
|
RU2623727C1 |
| AGENT SIMULATING CARDIAC POSTCONDITIONING PHENOMENON | 2012 |
|
RU2502508C1 |
| MEANS INCREASING HEART RESISTANCE TO REPERFUSION DAMAGE | 2016 |
|
RU2642826C1 |
| METHOD OF CARDIOPROTECTION OF ISCHEMIC AND REPERFUSION INJURIES IN ACUTE MYOCARDIAL INFARCTION | 2019 |
|
RU2712448C1 |
| AGENT FOR INCREASING RESISTANCE OF HEART TO ARRYTHMOGENIC ACTION OF ISCHAEMIA AND REPERFUSION | 2014 |
|
RU2587783C1 |
| AGENT IMPROVING BLOOD SUPPLY AND MYOCARDIAL METABOLISM | 2002 |
|
RU2225201C2 |
| AGENT POSSESSING CARDIOPROTECTIVE ACTIVITY | 2019 |
|
RU2699039C1 |
| CARDIOPROTECTIVE AGENT | 2020 |
|
RU2743764C1 |
| CARDIOPROTECTIVE AND ANTIARRHYTHMIC MEDICINE | 2022 |
|
RU2783444C1 |
| AGENT WITH CARDIOPROTECTIVE ACTIVITY | 2019 |
|
RU2791641C2 |
